Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14422266 | 1.00 | NPSR1 (0.34) | NPSR1 | |
| SCHEMBL1169566 | 0.93 | NPSR1 (0.35) | NPSR1 | |
| SCHEMBL1169568 | 0.93 | NPSR1 (0.35) | NPSR1 | |
| SCHEMBL4780770 | 0.91 | NPSR1 (0.35) | NPSR1 | |
| SCHEMBL1169660 | 0.91 | NPSR1 (0.35) | NPSR1 | |
| SCHEMBL4780773 | 0.91 | NPSR1 (0.35) | NPSR1 | |
| SCHEMBL14064605 | 0.89 | NPSR1 (0.37) | NPSR1 | |
| SCHEMBL1170141 | 0.85 | NPSR1 (0.34) | NPSR1 | |
| SCHEMBL12776810 | 0.82 | NPSR1 (0.32) | NPSR1 | |
| SCHEMBL2079406 | 0.81 | NPSR1 (0.32) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893055-B2 | pyrimido[2,1-c][1,4]oxazine-2-carboxamide, N-[(1,5-dimethyl-1H-pyrazol-3-yl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-; inhibits HIV integrase and prevent viral integration into human DNA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-22 | — | — | US | disclosed |
| US-7419969-B2 | HIV integrase inhibitors: cyclic pyrimidinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080004265-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-03 | — | — | US | disclosed |
| WO-2008002959-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-7273859-B2 | HIV integrase inhibitors: cyclic pyrimidinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004265-A1 | HIV Integrase Inhibitors | TYMP, POLN, IMPDH1 | NPSR1 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.